Industry
Biotechnology
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Loading...
Open
0.28
Mkt cap
15M
Volume
291K
High
0.32
P/E Ratio
-0.03
52-wk high
2.63
Low
0.28
Div yield
N/A
52-wk low
0.27
Portfolio Pulse from
November 14, 2024 | 1:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 12:41 pm
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Insights
October 02, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Insights
September 26, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
September 25, 2024 | 2:42 pm
Portfolio Pulse from Benzinga Insights
June 03, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
March 22, 2024 | 8:37 pm
Portfolio Pulse from Benzinga Insights
February 02, 2024 | 1:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.